 |
|
Enzyme inhibitor produces stable disease in patients with advanced solid cell cancers
November 08, 2006Phase II trials initiated
Prague, Czech Republic: Preliminary trials of a MEK enzyme inhibitor have shown that it is capable of producing long-lasting stable disease in patients with advanced solid cancers. Tests showed that the drug inhibited key targets in the patients' tumours, and now it is being tested in phase II clinical trials.
Professor Alex Adjei told the EORTC-NCI-AACR [1] Symposium on Molecular Targets and Cancer Therapeutics in Prague today (Wednesday 8 November) that the drug AZD6244 (ARRY-142886) [2] inhibited MEK1/2 - an enzyme that plays an important role in the Ras/Raf/MEK/ERK cell signalling pathway, which regulates cell proliferation and survival. Activation of this pathway has been implicated in a number of cancers, including lung, pancreatic, colon, melanoma and thyroid cancer.
"Laboratory studies have shown that AZD6244 has an effect on human tumours at nanomolar concentrations, and the first part of the phase I clinical trial has determined the maximum tolerated dose and the safety of the compound. Results from this second part of the trial demonstrate that a dose of 100mg of AZD6244 is well tolerated, produces a high incidence of long-lasting stable disease, and is associated with a profound inhibition of the cell signalling protein pERK and a reduction in cell proliferation - which indicates that the drug is working against the tumours," said Prof Adjei, who was professor of oncology at the Mayo Clinic, Rochester, USA, before moving in October to be the senior vice-president for clinical research and chair of the Department of Medicine at the Roswell Park Cancer Institute, Buffalo, USA.
Prof Adjei and his colleagues at the Mayo Clinic, University of Colorado Health Sciences Center and Fox Chase Cancer Center recruited into the second part of the trial 34 patients with advanced cancers, including melanoma, breast, lung and colorectal cancers. Approximately 40% of the patients had melanoma. The researchers were particularly interested in this tumour type because a large proportion harbour B-Raf mutations, and tumours with these mutations may be highly sensitive to MEK inhibitors.
The patients were randomised to receive 100 or 200mg doses, twice a day for 28-day cycles. The larger dose proved to be too high for continuous dosing due to adverse side effects, but the smaller dose was well tolerated over a prolonged period.
The researchers tested biopsy tissue taken from the patients both before and after dosing. They found that the pERK protein was reduced by 77%. They also looked at another protein, Ki-67, which is used as a marker for cell proliferation. After dosing, there was a reduction in Ki-67 in nine out of 20 patients, and in five of those nine patients the reduction was at least 50% or more.
"We found that after 15 days of dosing, AZD6244 continued to inhibit pERK at times when concentrations of the drug in the blood were at their lowest levels between doses. At the lowest concentration, 400 nanograms of the compound per microlitre of plasma still corresponded to a 35-44% inhibition of pERK," said Prof Adjei.
Overall, 39 of 57 patients completed at least one cycle of treatment with AZD6244. After completion of the second cycle, 19 (49%) had stable disease, and nine of these patients (six melanoma, one each of breast cancer, non-small cell lung cancer and medullary thyroid cancer) remained stable for five or more months (range, 5-14+ months; median, 6 months). Two patients, one with thyroid cancer and the other with melanoma, continue to receive treatment with AZD6244 after one year. Sixteen of the 20 patients with melanoma completed at least one cycle of treatment. Twelve had stable disease after completion of cycle two, with stable disease persisting for at least five months in six patients (range, 5-13+ months; median, 6.5 months).
Prof Adjei said: "This drug shows initial promising results. It appears to be able to target cancers with over-activation of MEK and associated cell signalling pathways in an efficient manner. Furthermore, it is easy to give to patients as it comes in an oral formulation that can be swallowed. As a result, a number of phase II clinical trials have been initiated in patients with melanoma, pancreatic, lung and colon cancers."
European Organisation for Research and Treatment of Cancer
"Laboratory studies have shown that AZD6244 has an effect on human tumours at nanomolar concentrations, and the first part of the phase I clinical trial has determined the maximum tolerated dose and the safety of the compound. Results from this second part of the trial demonstrate that a dose of 100mg of AZD6244 is well tolerated, produces a high incidence of long-lasting stable disease, and is associated with a profound inhibition of the cell signalling protein pERK and a reduction in cell proliferation - which indicates that the drug is working against the tumours," said Prof Adjei, who was professor of oncology at the Mayo Clinic, Rochester, USA, before moving in October to be the senior vice-president for clinical research and chair of the Department of Medicine at the Roswell Park Cancer Institute, Buffalo, USA.
Prof Adjei and his colleagues at the Mayo Clinic, University of Colorado Health Sciences Center and Fox Chase Cancer Center recruited into the second part of the trial 34 patients with advanced cancers, including melanoma, breast, lung and colorectal cancers. Approximately 40% of the patients had melanoma. The researchers were particularly interested in this tumour type because a large proportion harbour B-Raf mutations, and tumours with these mutations may be highly sensitive to MEK inhibitors.
The patients were randomised to receive 100 or 200mg doses, twice a day for 28-day cycles. The larger dose proved to be too high for continuous dosing due to adverse side effects, but the smaller dose was well tolerated over a prolonged period.
The researchers tested biopsy tissue taken from the patients both before and after dosing. They found that the pERK protein was reduced by 77%. They also looked at another protein, Ki-67, which is used as a marker for cell proliferation. After dosing, there was a reduction in Ki-67 in nine out of 20 patients, and in five of those nine patients the reduction was at least 50% or more.
"We found that after 15 days of dosing, AZD6244 continued to inhibit pERK at times when concentrations of the drug in the blood were at their lowest levels between doses. At the lowest concentration, 400 nanograms of the compound per microlitre of plasma still corresponded to a 35-44% inhibition of pERK," said Prof Adjei.
Overall, 39 of 57 patients completed at least one cycle of treatment with AZD6244. After completion of the second cycle, 19 (49%) had stable disease, and nine of these patients (six melanoma, one each of breast cancer, non-small cell lung cancer and medullary thyroid cancer) remained stable for five or more months (range, 5-14+ months; median, 6 months). Two patients, one with thyroid cancer and the other with melanoma, continue to receive treatment with AZD6244 after one year. Sixteen of the 20 patients with melanoma completed at least one cycle of treatment. Twelve had stable disease after completion of cycle two, with stable disease persisting for at least five months in six patients (range, 5-13+ months; median, 6.5 months).
Prof Adjei said: "This drug shows initial promising results. It appears to be able to target cancers with over-activation of MEK and associated cell signalling pathways in an efficient manner. Furthermore, it is easy to give to patients as it comes in an oral formulation that can be swallowed. As a result, a number of phase II clinical trials have been initiated in patients with melanoma, pancreatic, lung and colon cancers."
European Organisation for Research and Treatment of Cancer
Science News and Science Current Events Tag Cloud
This tag cloud is a visual representation of term frequencies of random science news topics with common terms grouped together and emphasized by their display size.
Retinoic Acid Life Expectancy Heart Surgery Neurological Disease Cancer Cells Bisphosphonates Parasite Tamoxifen Parkinson’s Disease Antibiotic Resistance Diabetes Thyroid Brain Size Quantum Computers Salmon Quantum Computing Radiofrequency Ablation Seizures Sleep-disordered Breathing Bone Loss Macrophages Smart-1 Spiders Biodiesel Hydrothermal Vent
See More: Science News Tags
Enzyme Inhibitor Current Events and Enzyme Inhibitor News RSSNovel enzyme inhibitor paves way for new cancer drug
Combining natural organic atoms with metal complexes, scientists at The Wistar Institute have developed a new type of enzyme inhibitor capable of blocking a biochemical pathway that plays a key role in cancer development.
Chronic kidney disease rises while most people with the condition remain unaware
A growing number of Americans have chronic kidney disease, but most remain unaware of it, hampering efforts to prevent irreversible kidney failure requiring dialysis or a transplant.
Scientists discover way to block growth of prostate cancer cells
Scientists have discovered for the first time a specific biochemical pathway by which the sex hormone, androgen, increases levels of harmful chemicals called reactive oxygen species (ROS) in the prostate gland that play a role in the development of prostate cancer.
Pest control research leads to pain control discovery
A newly discovered enzyme inhibitor, identified by researchers originally looking for biological pest controls, may lead to pain relief for sufferers of arthritis and other inflammatory diseases.
Polycystic kidney disease
The National Institutes of Health (NIH) and the PKD Foundation have launched two treatment trials for autosomal dominant polycystic kidney disease (ADPKD).
Defeating the 'superpests'
Scientists have developed a new technique that makes pesticides more effective by removing insects' ability to exhibit resistance.
Blood pressure treatment could cut risk of strokes and heart attacks
A new treatment strategy for hypertension can cut the risk of strokes by around 25 percent and coronary events by around 15 percent according to the preliminary results of a major international trial announced at the American College of Cardiology Late Breaking Clinical Trials II Meeting in Orlando today.
Success of new treatment halts international blood pressure drug trial
An international trial comparing blood-pressure lowering treatments has been stopped early due to the significantly better performance of one of the treatments in the trial.
ESC Spokespersons assess the viability of the 'Polypill' for cardiovascular disease prevention
ESC Spokespersons speak out on the concept of the 'Polypill', proposed by British scientists as a daily formula of six medications, to be taken by heart patients and all those over 55 years old, to avert more than 80 percent of heart attacks and strokes. The 'Polypill', proposed by Dr Nicolas Wald and Dr Malcolm Law of the University of London, consists of a statin or simvastatin to lower cholesterol, three blood pressure lowering drugs at standard half dose (e.g. a thiazide, a beta-blocker and an angiotensin converting enzyme inhibitor), folic acid to reduce levels of homocysteine and subsequent atherosclerosis, and aspirin. Wald and Law suggest that the 'Polypill' could provide combined t
Study finds drug can cut chance of a heart attack by more than a third
Results from the ASCOT (Anglo Scandinavian Cardiac Outcome Trial) study have shown that patients receiving the cholesterol controlling drug, atorvastatin, are more than a third less likely to have heart attacks, and more than a quarter less likely to suffer from strokes. The results of the study, announced today at the American College of Cardiology annual scientific session in Chicago, USA, and simultaneously published online in the Lancet, show that in a study of more than 10,305 people with high blood pressure and normal or only moderately raised levels of cholesterol, those receiving atorvastatin were 36 percent less likely to suffer from heart attacks, and 27 percent less likely to suff
More Enzyme Inhibitor Current Events and Enzyme Inhibitor News Articles
 |
Evaluation of Enzyme Inhibitors in Drug Discovery: A Guide for Medicinal Chemists and Pharmacologists (Methods of Biochemical Analysis) by Robert A. Copeland (Author) Vital information for discovering and optimizing new drugs "Understanding the data and the experimental details that support it has always been at the heart of good science and the assumption challenging process that leads from good science to drug discovery. This book helps medicinal chemists and pharmacologists to do exactly that in the realm of enzyme inhibitors." -Paul S. Anderson, PhD This publication provides readers with a thorough understanding of enzyme-inhibitor evaluation to assist them in their efforts to discover and optimize novel drug therapies. Key topics such as competitive, noncompetitive, and uncompetitive inhibition, slow binding, tight binding, and the use of Hill coefficients to study reaction stoichiometry are all presented. Examples of key... |
 |
Evaluation of Enzyme Inhibitors in Drug Discovery: A Guide for Medicinal Chemists and Pharmacologists (Methods of Biochemical Analysis) by Wiley-Interscience Vital information for discovering and optimizing new drugs "Understanding the data and the experimental details that support it has always been at the heart of good science and the assumption challenging process that leads from good science to drug discovery. This book helps medicinal chemists and pharmacologists to do exactly that in the realm of enzyme inhibitors." -Paul S. Anderson, PhD This publication provides readers with a thorough understanding of enzyme-inhibitor evaluation to assist them in their efforts to discover and optimize novel drug therapies. Key topics such as competitive, noncompetitive, and uncompetitive inhibition, slow binding, tight binding, and the use of Hill coefficients to study reaction stoichiometry are all presented. Examples of key... |
 |
Bromelain 2000 GDU/Gram, 500 mg, 60 Tablets by Bromelain 2000 GDU/Gram, 500 mg, 60 Tablets - Provided by Physician Formulas Bromelain is an enzyme from the pineapple plant which accelerates the breakdown of proteins. It is active in a wide pH range and can function in the acidic environment of the stomach. Bromelain is a combination of several protein-digesting enzymes along with peroxidase, acid phosphatase, protease inhibitors, and calcium. Bromelain is most often used to help digestion and help reduce inflammation. |
 |
Enzymes and Their Inhibitors: Drug Development (Enzyme Inhibitors) by H. John Smith (Editor), Claire Simons (Editor) Focusing on the development of enzyme inhibitors as therapeutic drugs, this textbook provides a concise overview of the chemistry of major types of enzymes and their inhibitors.The opening chapters introduce the reader to the structure, functions, mechanisms and kinetics of enzymes, including the use of enzymes as disease markers, analytical reagents and their use in industrial processes. Subsequent chapters discuss the different types of enzyme inhibitors and the basic principles involved in developing them into an effective drug, from discovery of the lead compound to their use in the clinic. An extremely useful text for all students of pharmacy and medicinal chemistry. |
 |
Design of Caspase Inhibitors as Potential Clinical Agents (Crc Enzyme Inhibitors) by Tom O'Brien (Editor), Steven D. Linton (Editor) Caspases (cysteine aspartyl proteases) represent one of the most specific protease families described to date. As caspase family members are involved in pro-inflammatory responses, inhibition of caspase activity represents a novel yet core approach to disease treatment. Design of Caspase Inhibitors as Potential Clinical Agents discusses the role of caspases in inducing cell death. It reviews recent efforts to develop small molecule inhibitors that are capable of modulating caspase activity. The text also examines the difficulties encountered in transitioning small molecule inhibitors from the lab to clinical use, and discusses how these challenges can best be overcome to allow continued progress. |
 |
ProntoPass Naplex Review Liver Enzymes Poster by ProntoPass Solutions Liver Enzymes 11" x 17" Poster. Great visual adjunct to regular ProntoPass® QUICKCARDS® Naplex® Review study material. Visualize the material and burn it into your brain. Evolutionary educational change, revolutionary results. Liver Enzymes is important to know for NAPLEX®. Printed on both sides. ProntoPass® - the prescription for success. |
 |
Handbook of Enzyme Inhibitors 4-volume set by Helmward Zollner (Author) The Third Edition of this successful standard reference work is available now. Compared to the Second Edition the the amount of data contained has tripled! Approximately 52,000 entries provide a wealth of information for the specialist in the field. The proven organization of the work in two parts has been maintained: you can search from enzyme to inhibitor (Part A) and from inhibitor to enzyme (Part B). Useful entries, e.g. on the type of inhibition or the effective concentration are given as well as comments on organisms and products and an extensive documentation of references. This impressive reference work is indispensable for every expert in life sciences, medicine and pharmacology working with enzymes. |
|
Enzyme Inhibitors as Drugs (Biological Council Symposia on Drug Action) by Merton Sandler (Author) | |
|
Design of Enzyme Inhibitors As Drugs: Volume 2 by Merton Sandler (Editor), H. John Smith (Editor) A high proportion of drugs currently coming to market exert their action in the body by inhibiting a target enzyme involved in a particular body function or in a bacterium, protozoon, or virus causing an infection. This book extends the previous volume in providing a comprehensive coverage of more recently recognized target enzymes and their known inhibitors and, within this framework of knowledge, demonstrates how the drug designer uses all available information to develop a specific therapeutic agent. Drug design is an interdisciplinary art; this text illustrates the pathway followed from the initial design concept and synthesis of an inhibitor, through its in vitro and in vivo assessments, to clinical trial -- a process involving chemists, biochemists, pharmacologists, and clinicians. | |
 |
ACE Inhibitors (Milestones in Drug Therapy) by Birkhäuser Basel The therapeutic use of angiotensin converting enzyme (ACE) inhibitors is subject of this monograph, written by international experts in the field. Elegantly introduced by a historical perspective by Sir John Vane, Nobel Laureate, the book covers major topics ranging from the molecular basis of the ACE inhibitors to their application in several diseases of paramount importance such as hypertension, renal failure, diabetes and heart failure. Additional contributions address the multitude of peripheral factors which may modulate the efficacy and/or activity of the ACE inhibitors. From a description of the genetic basis of ACE to epidemiological considerations on these potent molecules, this treatise should be of great benefit to clinical and non-clinical scientists, residents, the... |
| © 2009 BrightSurf.com |